Lung cancer histologic and immunohistochemical heterogeneity in the era of molecular therapies: Analysis of 172 consecutive surgically resected, entirely sampled pulmonary carcinomas

Annamaria Cadioli, Giulio Rossi, Matteo Costantini, Alberto Cavazza, Mario Migaldi, Thomas V. Colby

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

On the basis of seminal studies in the 1980s, appreciable histologic heterogeneity, ranging from 45% to 70% of cases, may be encountered in lung cancer. However, the epidemiologic and histologic landscape of lung cancer in the last 3 decades has radically changed. In this study, 172 consecutive surgically resected primary lung carcinomas evaluated from 2010 to 2012 were entirely sampled and examined according to current histologic classifications. In 129 cases, a positive preoperative biopsy was also available. Major histologic heterogeneity (a single tumor showing at least 2 different histologic types) and minor histologic heterogeneity (a single tumor showing just 1 histologic type but at least 2 different growth patterns) were evaluated in all cases. Immunohistochemical heterogeneity (ie, "aberrant" staining) was also assessed using a panel of markers of adenocarcinoma (TTF-1, napsin, and CK7), squamous cell carcinoma (p63, CK5/6), and neuroendocrine differentiation (chromogranin and synaptophysin), both on positive biopsies and surgical specimens. Overall, major and minor histologic heterogeneity on resections were disclosed in 4% (7 cases) and 50.6% (87 cases), respectively, whereas just 1 case of minor heterogeneity (pleomorphic carcinoma) was observed on biopsies. Minor heterogeneity was limited to adenocarcinomas (82.6%, 81/98 cases) and sarcomatoid carcinomas (6 pleomorphic types among 8 sarcomatoid carcinomas). Immunohistochemical heterogeneity was recorded in 22.6% of the cases, with expression of p63 and CK5/6 in a subset of adenocarcinomas (25 cases, 25.5%), CK7 in 17.4% of squamous cell carcinomas, and synaptophysin in 6 cases of non-neuroendocrine tumors (4%, 6/155). The high rate of adenocarcinomas, accounting for 57% (98 cases) of 172 consecutively resected lung cancers, reflects the new scenario of thoracic oncology and may explain the significant lower rate of major histologic heterogeneity (4%) and the higher frequency of different architectural patterns (minor heterogeneity) that we found in lung cancer compared with previous studies.

Original languageEnglish
Pages (from-to)502-509
Number of pages8
JournalAmerican Journal of Surgical Pathology
Volume38
Issue number4
DOIs
Publication statusPublished - 2014

Fingerprint

Lung Neoplasms
Adenocarcinoma
Carcinoma
Lung
Synaptophysin
Biopsy
Squamous Cell Carcinoma
Chromogranins
Neoplasms
Therapeutics
Thorax
Staining and Labeling
Growth

Keywords

  • Adenocarcinoma
  • Heterogeneity
  • Histotype
  • Immunohistochemistry
  • Lung cancer
  • NSCLC

ASJC Scopus subject areas

  • Anatomy
  • Pathology and Forensic Medicine
  • Surgery

Cite this

Lung cancer histologic and immunohistochemical heterogeneity in the era of molecular therapies : Analysis of 172 consecutive surgically resected, entirely sampled pulmonary carcinomas. / Cadioli, Annamaria; Rossi, Giulio; Costantini, Matteo; Cavazza, Alberto; Migaldi, Mario; Colby, Thomas V.

In: American Journal of Surgical Pathology, Vol. 38, No. 4, 2014, p. 502-509.

Research output: Contribution to journalArticle

@article{4a4df812fc1b45e791d05f13d52579a9,
title = "Lung cancer histologic and immunohistochemical heterogeneity in the era of molecular therapies: Analysis of 172 consecutive surgically resected, entirely sampled pulmonary carcinomas",
abstract = "On the basis of seminal studies in the 1980s, appreciable histologic heterogeneity, ranging from 45{\%} to 70{\%} of cases, may be encountered in lung cancer. However, the epidemiologic and histologic landscape of lung cancer in the last 3 decades has radically changed. In this study, 172 consecutive surgically resected primary lung carcinomas evaluated from 2010 to 2012 were entirely sampled and examined according to current histologic classifications. In 129 cases, a positive preoperative biopsy was also available. Major histologic heterogeneity (a single tumor showing at least 2 different histologic types) and minor histologic heterogeneity (a single tumor showing just 1 histologic type but at least 2 different growth patterns) were evaluated in all cases. Immunohistochemical heterogeneity (ie, {"}aberrant{"} staining) was also assessed using a panel of markers of adenocarcinoma (TTF-1, napsin, and CK7), squamous cell carcinoma (p63, CK5/6), and neuroendocrine differentiation (chromogranin and synaptophysin), both on positive biopsies and surgical specimens. Overall, major and minor histologic heterogeneity on resections were disclosed in 4{\%} (7 cases) and 50.6{\%} (87 cases), respectively, whereas just 1 case of minor heterogeneity (pleomorphic carcinoma) was observed on biopsies. Minor heterogeneity was limited to adenocarcinomas (82.6{\%}, 81/98 cases) and sarcomatoid carcinomas (6 pleomorphic types among 8 sarcomatoid carcinomas). Immunohistochemical heterogeneity was recorded in 22.6{\%} of the cases, with expression of p63 and CK5/6 in a subset of adenocarcinomas (25 cases, 25.5{\%}), CK7 in 17.4{\%} of squamous cell carcinomas, and synaptophysin in 6 cases of non-neuroendocrine tumors (4{\%}, 6/155). The high rate of adenocarcinomas, accounting for 57{\%} (98 cases) of 172 consecutively resected lung cancers, reflects the new scenario of thoracic oncology and may explain the significant lower rate of major histologic heterogeneity (4{\%}) and the higher frequency of different architectural patterns (minor heterogeneity) that we found in lung cancer compared with previous studies.",
keywords = "Adenocarcinoma, Heterogeneity, Histotype, Immunohistochemistry, Lung cancer, NSCLC",
author = "Annamaria Cadioli and Giulio Rossi and Matteo Costantini and Alberto Cavazza and Mario Migaldi and Colby, {Thomas V.}",
year = "2014",
doi = "10.1097/PAS.0000000000000154",
language = "English",
volume = "38",
pages = "502--509",
journal = "American Journal of Surgical Pathology",
issn = "0147-5185",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Lung cancer histologic and immunohistochemical heterogeneity in the era of molecular therapies

T2 - Analysis of 172 consecutive surgically resected, entirely sampled pulmonary carcinomas

AU - Cadioli, Annamaria

AU - Rossi, Giulio

AU - Costantini, Matteo

AU - Cavazza, Alberto

AU - Migaldi, Mario

AU - Colby, Thomas V.

PY - 2014

Y1 - 2014

N2 - On the basis of seminal studies in the 1980s, appreciable histologic heterogeneity, ranging from 45% to 70% of cases, may be encountered in lung cancer. However, the epidemiologic and histologic landscape of lung cancer in the last 3 decades has radically changed. In this study, 172 consecutive surgically resected primary lung carcinomas evaluated from 2010 to 2012 were entirely sampled and examined according to current histologic classifications. In 129 cases, a positive preoperative biopsy was also available. Major histologic heterogeneity (a single tumor showing at least 2 different histologic types) and minor histologic heterogeneity (a single tumor showing just 1 histologic type but at least 2 different growth patterns) were evaluated in all cases. Immunohistochemical heterogeneity (ie, "aberrant" staining) was also assessed using a panel of markers of adenocarcinoma (TTF-1, napsin, and CK7), squamous cell carcinoma (p63, CK5/6), and neuroendocrine differentiation (chromogranin and synaptophysin), both on positive biopsies and surgical specimens. Overall, major and minor histologic heterogeneity on resections were disclosed in 4% (7 cases) and 50.6% (87 cases), respectively, whereas just 1 case of minor heterogeneity (pleomorphic carcinoma) was observed on biopsies. Minor heterogeneity was limited to adenocarcinomas (82.6%, 81/98 cases) and sarcomatoid carcinomas (6 pleomorphic types among 8 sarcomatoid carcinomas). Immunohistochemical heterogeneity was recorded in 22.6% of the cases, with expression of p63 and CK5/6 in a subset of adenocarcinomas (25 cases, 25.5%), CK7 in 17.4% of squamous cell carcinomas, and synaptophysin in 6 cases of non-neuroendocrine tumors (4%, 6/155). The high rate of adenocarcinomas, accounting for 57% (98 cases) of 172 consecutively resected lung cancers, reflects the new scenario of thoracic oncology and may explain the significant lower rate of major histologic heterogeneity (4%) and the higher frequency of different architectural patterns (minor heterogeneity) that we found in lung cancer compared with previous studies.

AB - On the basis of seminal studies in the 1980s, appreciable histologic heterogeneity, ranging from 45% to 70% of cases, may be encountered in lung cancer. However, the epidemiologic and histologic landscape of lung cancer in the last 3 decades has radically changed. In this study, 172 consecutive surgically resected primary lung carcinomas evaluated from 2010 to 2012 were entirely sampled and examined according to current histologic classifications. In 129 cases, a positive preoperative biopsy was also available. Major histologic heterogeneity (a single tumor showing at least 2 different histologic types) and minor histologic heterogeneity (a single tumor showing just 1 histologic type but at least 2 different growth patterns) were evaluated in all cases. Immunohistochemical heterogeneity (ie, "aberrant" staining) was also assessed using a panel of markers of adenocarcinoma (TTF-1, napsin, and CK7), squamous cell carcinoma (p63, CK5/6), and neuroendocrine differentiation (chromogranin and synaptophysin), both on positive biopsies and surgical specimens. Overall, major and minor histologic heterogeneity on resections were disclosed in 4% (7 cases) and 50.6% (87 cases), respectively, whereas just 1 case of minor heterogeneity (pleomorphic carcinoma) was observed on biopsies. Minor heterogeneity was limited to adenocarcinomas (82.6%, 81/98 cases) and sarcomatoid carcinomas (6 pleomorphic types among 8 sarcomatoid carcinomas). Immunohistochemical heterogeneity was recorded in 22.6% of the cases, with expression of p63 and CK5/6 in a subset of adenocarcinomas (25 cases, 25.5%), CK7 in 17.4% of squamous cell carcinomas, and synaptophysin in 6 cases of non-neuroendocrine tumors (4%, 6/155). The high rate of adenocarcinomas, accounting for 57% (98 cases) of 172 consecutively resected lung cancers, reflects the new scenario of thoracic oncology and may explain the significant lower rate of major histologic heterogeneity (4%) and the higher frequency of different architectural patterns (minor heterogeneity) that we found in lung cancer compared with previous studies.

KW - Adenocarcinoma

KW - Heterogeneity

KW - Histotype

KW - Immunohistochemistry

KW - Lung cancer

KW - NSCLC

UR - http://www.scopus.com/inward/record.url?scp=84896601759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896601759&partnerID=8YFLogxK

U2 - 10.1097/PAS.0000000000000154

DO - 10.1097/PAS.0000000000000154

M3 - Article

C2 - 24441660

AN - SCOPUS:84896601759

VL - 38

SP - 502

EP - 509

JO - American Journal of Surgical Pathology

JF - American Journal of Surgical Pathology

SN - 0147-5185

IS - 4

ER -